Symptoms assessment and decision to treat patients with advanced Parkinson’s disease based on wearables data

[1]  R. Dahlstrom,et al.  Challenges and opportunities , 2021, Foundations of a Sustainable Economy.

[2]  Francesca Morgante,et al.  Prediction of the Levodopa Challenge Test in Parkinson’s Disease Using Data from a Wrist-Worn Sensor , 2019, Sensors.

[3]  K. Chaudhuri,et al.  Non-motor correlates of wrist-worn wearable sensor use in Parkinson’s disease: an exploratory analysis , 2019, npj Parkinson's Disease.

[4]  F. Nahab,et al.  Evaluation of Clinical Utility of the Personal KinetiGraph® in the Management of Parkinson Disease , 2019, Advances in Parkinson's Disease.

[5]  Malcolm Horne,et al.  The Use of Data from the Parkinson’s KinetiGraph to Identify Potential Candidates for Device Assisted Therapies , 2019, Sensors.

[6]  James W. Langston,et al.  Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson’s Clinic , 2018, Journal of Parkinson's disease.

[7]  G. Deuschl,et al.  Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial , 2018, The Lancet Neurology.

[8]  Rajesh Pahwa,et al.  Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel , 2018, Expert review of neurotherapeutics.

[9]  E. Dietrichs,et al.  Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease , 2018, npj Parkinson's Disease.

[10]  Jerker Westin,et al.  Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry , 2018, CNS neuroscience & therapeutics.

[11]  A. Evans,et al.  Objective measurement in routine care of people with Parkinson’s disease improves outcomes , 2018, npj Parkinson's Disease.

[12]  P. Churchward,et al.  The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson’s disease , 2018, npj Parkinson's Disease.

[13]  Parisa Farzanehfar,et al.  An Ambulatory Tremor Score for Parkinson's Disease. , 2016, Journal of Parkinson's disease.

[14]  Max A. Little,et al.  Technology in Parkinson's disease: Challenges and opportunities , 2016, Movement disorders : official journal of the Movement Disorder Society.

[15]  Leonid Churilov,et al.  Correlation of Quantitative Motor State Assessment Using a Kinetograph and Patient Diaries in Advanced PD: Data from an Observational Study , 2016, PloS one.

[16]  P Martinez-Martin,et al.  Night‐time sleep in Parkinson's disease – the potential use of Parkinson's KinetiGraph: a prospective comparative study , 2016, European journal of neurology.

[17]  Dimitrios I. Fotiadis,et al.  Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform , 2016, 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[18]  E. Dietrichs,et al.  Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. , 2015, Parkinsonism & related disorders.

[19]  A. Rodríguez-Molinero,et al.  Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept. , 2015, Parkinsonism & related disorders.

[20]  M. Horne,et al.  An Objective Fluctuation Score for Parkinson's Disease , 2015, PloS one.

[21]  V. Fung,et al.  Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results , 2014, Movement disorders : official journal of the Movement Disorder Society.

[22]  J. Friedman.  Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial , 2014, Neurology.

[23]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[24]  Grant D. Huang,et al.  Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. , 2009, JAMA.

[25]  T. Sozu,et al.  Effective number of subjects and number of raters for inter‐rater reliability studies , 2006, Statistics in medicine.

[26]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[27]  L. Moreland,et al.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.

[28]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[29]  S. Ferrari,et al.  Author contributions , 2021 .

[30]  Juan Manuel Moreno,et al.  A "HOLTER" for Parkinson's disease: Validation of the ability to detect on-off states using the REMPARK system. , 2018, Gait & posture.

[31]  J. Cabestany,et al.  The REMPARK System , 2017 .

[32]  Royster C. Hedgepeth.  An Exploratory Analysis , 2016 .

[33]  K. Kotschet,et al.  The Clinical validation of objective Measurement of Movement in Parkinson ’ s Disease , 2016 .

[34]  M. Horne,et al.  Can Objective Measurements Improve Treatment Outcomes in Parkinson’s Disease? , 2014 .

[35]  P. Kempster,et al.  Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. , 2012, Journal of Parkinson's disease.

[36]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .